FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
News|Articles|September 3, 2026
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
Author(s)Alex Biese
Fact checked by: By ONN Staff
Oncology nursing guide to the FDA approval of zanidatamab-hrii for HER2+ gastroesophageal cancers, featuring insights from Joe Chichioco, RN, MPH.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has approved the HER2-directed bispecific antibody zanidatamab-hrii (Ziihera) as a first-line therapy for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
Related to this article
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves cabozantinib capsules for RCC, HCC, and epNET. Review key dosing conversions and safety guidelines for oncology nursing practice.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA grants accelerated approval to sevabertinib (Hyrnuo) for HER2 TKD-mutant non-squamous NSCLC, expanding access to treatment-naive patients.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- advanced breast cancer.
Experts share critical clinical protocols for managing daraxonrasib (Rasonque) following its landmark FDA approval.
Advertisement
Advertisement